Contributor Cindy H. Dubin posed a series of questions to several CDMOs to find out how they are positioned to help Pharma navigate the waters of patent expirations, rising costs, shrinking timelines, and budget constraints.
DRUG DEVELOPMENT – Design & Development of Atorvastatin Orally Disintegrating Tablets & Their Evaluation by Electronic Tongue
Rakesh Kumar Bhasin, MPharm, and Pradip Kumar Ghosh, PhD, design and develop a good taste-masked atorvastatin ODT that matched the in vitro release profile of Lipitor.
FORMULATION DEVELOPMENT – In Vitro Diffusion Studies in Transdermal Research: A Synthetic Membrane Model in Place of Human Skin
Vivek Joshi, PhD, David Brewster, and Peter Colonero present data on the applicability of a synthetic membrane (Strat-MTM) for in vitro transdermal diffusion studies in place of human or animal skin as a model.
Suniket Fulzele, PhD; Derek Moe, PhD; and Ehab Hamed, PhD; review the lyophilized wafer technology, specifically Lyoc, that offered the world’s first ODT, ODA Lyoc (sodium saccharinate and flamenol) in 1968.
THERAPEUTIC FOCUS – Therapeutic Advances in Non-Small Cell Lung Cancer: Targeting Activating & Resistant Forms of EGFR & ALK
William C. Shakespeare, PhD, provides a brief review of both targets, including approved agents, mechanisms of resistance, and next-generation agents in development; many designed specifically to target disease-resistant mutations.
Anand Shah, MPharm; Sunny Shah, MPharm; Vipul Patel, MPharm, PhD; and Arti Potdar, MPharm; review the various approaches adapted to nanonize the drug, the characterization of the prepared drug nanoparticles, and their applications.
DRUG DEVELOPMENT – Advancing Personalized Medicine: A Seamless Solution to Discover & Deliver Novel Diagnostic Tests
The use of companion diagnostics in conjunction with custom pharmaceuticals is expected to expand as the promise of personalized medicine continues to be realized. However, a concurrent development cycle of both diagnostic and therapeutic requires a complex synergy of both diagnostic and drug development, and represents a significant deviation from the current pharmaceutical model.
Dr. Marc Mansour, Chief Operating Officer & Chief Science Officer of Immunovaccine, discusses the DepoVax platform and the companyâ€™s clinical trials for DPX-0907 and DPX-Survivac.
EXECUTIVE INTERVIEW – NanoSmart Pharmaceuticals: Patented Delivery Platform Using Human Autoimmune Antibodies to Target Cancers & Other Debilitating Diseases
Dr. James Smith, President of NanoSmart Pharmaceuticals, discusses his company’s innovative approach to drug delivery using immunoliposomes and their unique targeting ability.
FORMULATION DEVELOPMENT – Oral Administration of an Insulin-Soybean Suspension in Streptozocin Rats: Effect of Aqueous Soybean Extract Vehicle
Antoine Al-Achi, PhD; Brijesh Patel, MS; and Sejal Patel, MS; investigate in this study the hypoglycemic activity of an insulin suspension given orally in a vehicle of soybean extract to streptozocin diabetic rats.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
Accenture recently announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its……
Sanofi and Abbott are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes……
AC Immune SA recently announced it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of….
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….